# HOOKIPA Pharma Announces Board of Directors Changes
Canonical URL: https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-board-of-directors-changes-97acc5a1
Ticker: HOOK
Company: HOOKIPA Pharma Inc.
Source: HOOKIPA Pharma Inc.
Published: 2024-08-30 12:00 EST
## Summary

HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class...

## Article Body
HOOKIPA Pharma Inc. (NASDAQ: HOOK) (“HOOKIPA” or the “Company”), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced the appointment of Director Julie O’Neill as Non-Executive Chair of the Company’s Board of Directors. She succeeds Jan van de Winkel, who has decided to step down from the Board effective August 30, 2024, due to increasing time commitments from his executive position as Chief Executive Officer of Genmab A/S. The Company also announced that Tim Reilly has chosen to step down from the Board, also effective August 30th, to be able to dedicate more time to his other professional responsibilities.

“On behalf of the entire Board, I want to thank Jan for his more than seven years of loyal service and inspirational leadership of the Board of Directors and Tim for his insights and perspectives,” said Ms. O’Neill. “We understand their demanding schedules and are grateful for the years of service they provided HOOKIPA. I look forward to working with the management team on behalf of our shareholders and other stakeholders.”

Messrs. van de Winkel’s and Reilly’s board seats will remain unfilled, and the Board will comprise five members.

About HOOKIPA HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, KRAS-mutated cancers, and other undisclosed programs. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead. Find out more about HOOKIPA online at www.hookipapharma.com .

For further information, please contact:

Investors Chuck Padala Managing Director, LifeSci Advisors chuck@lifesciadvisors.com

Media Tom Davies / Ashe Reardon tom.davies@kekstcnc.com / ashe.reardon@kekstcnc.com
## Recent Company News
- 2026-03-26 11:00 EST — [HOOKIPA Pharma Announces Completion of Sale of Oncology Assets to NeoTrail Therapeutics](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-completion-of-sale-of-oncology-assets-to-neotrail-thera-ff442692) — Source: HOOKIPA Pharma Inc.
- 2026-02-03 13:30 EST — [HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-sale-of-oncology-assets-to-neotrail-therapeutics-03f4fec9) — Source: HOOKIPA Pharma Inc.
- 2025-10-31 12:00 EST — [HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-completion-of-sale-of-hbv-and-hiv-assets-to-gilead-204a9211) — Source: HOOKIPA Pharma Inc.
- 2025-07-18 20:05 EST — [HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock](https://biopharmsignal.com/news/HOOK/hookipa-pharma-announces-intention-to-voluntarily-delist-and-deregister-its-comm-9406013c) — Source: HOOKIPA Pharma Inc.
- 2025-02-20 20:06 EST — [HOOKIPA Pharma Inc. (“HOOKIPA”) Statement regarding potential combination for Poolbeg Pharma plc (“Poolbeg”)](https://biopharmsignal.com/news/HOOK/hookipa-pharma-inc-hookipa-statement-regarding-potential-combination-for-poolbeg-5cecd13c) — Source: HOOKIPA Pharma Inc.
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)